CBX-12 is under clinical development by Cybrexa and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CBX-12’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CBX-12 overview

CBX-12 is under development for the treatment of solid tumors including small cell lung cancer, metastatic breast cancer and platinum-resistant ovarian cancer. The drug candidate a peptide drug conjugate (PDC) delivering exatecan. It is being developed based on peptide-based alphalex technology. It is administered through intravenous route. It was also under development for the treatment of triple-negative breast cancer and colorectal cancer.

Cybrexa overview

Cybrexa is a biotechnology company that develops novel therapeutics for the treatment of oncology. Its pipeline program includes alphalex exactecam (CBX-12), alphalex MMAE (CBX-15), alphalex DM4 (CBX-13), alphalex multi-targeted DDR inhibitor (CBX-14) and others. The company develops small molecules that inhibit DNA repair and potential to induce acute levels of chemo- and radio-sensitization in solid tumors. It enhanced a peptide-based technology to develop Tumor-Specific Drugs (TSDs). Cybrexa peptides deliver small molecules across the lipid bilayers of cells that are specifically under low pH conditions. The company provides TSDs that can be used with both existing and new DNA repair inhibitors. Cybrexa is headquartered in New Haven, Connecticut, the US.

For a complete picture of CBX-12’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.